Motley Fool Asset Management LLC Purchases 2,983 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Motley Fool Asset Management LLC grew its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 18.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,248 shares of the medical equipment provider’s stock after purchasing an additional 2,983 shares during the period. Motley Fool Asset Management LLC’s holdings in Intuitive Surgical were worth $10,047,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Atala Financial Inc bought a new stake in Intuitive Surgical in the 4th quarter worth approximately $25,000. Berbice Capital Management LLC bought a new stake in shares of Intuitive Surgical in the 4th quarter worth approximately $26,000. BankPlus Trust Department purchased a new stake in shares of Intuitive Surgical in the 4th quarter valued at $28,000. Summit Securities Group LLC bought a new position in shares of Intuitive Surgical during the 4th quarter valued at $30,000. Finally, Kohmann Bosshard Financial Services LLC purchased a new position in Intuitive Surgical in the 4th quarter worth $31,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Amal M. Johnson sold 4,635 shares of the company’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total value of $2,626,191.00. Following the sale, the director now directly owns 12,275 shares of the company’s stock, valued at $6,955,015. This represents a 27.41 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Jamie Samath sold 269 shares of Intuitive Surgical stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $590.00, for a total transaction of $158,710.00. Following the transaction, the chief financial officer now directly owns 3,282 shares of the company’s stock, valued at approximately $1,936,380. This trade represents a 7.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 33,754 shares of company stock valued at $17,691,621 over the last ninety days. Company insiders own 0.70% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG opened at $507.05 on Thursday. The firm has a market capitalization of $180.60 billion, a P/E ratio of 79.10, a P/E/G ratio of 5.85 and a beta of 1.43. The stock has a 50 day moving average price of $550.11 and a 200-day moving average price of $532.84. Intuitive Surgical, Inc. has a 52-week low of $364.17 and a 52-week high of $616.00.

Analyst Ratings Changes

ISRG has been the subject of several analyst reports. Leerink Partners upped their price target on shares of Intuitive Surgical from $490.00 to $548.00 in a research report on Monday, January 27th. Evercore ISI raised their price target on Intuitive Surgical from $490.00 to $530.00 in a research report on Monday, January 27th. Erste Group Bank cut Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 17th. Barclays increased their price objective on Intuitive Surgical from $610.00 to $674.00 in a research note on Monday, January 27th. Finally, Citigroup lifted their target price on shares of Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a research note on Friday, January 24th. One analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $611.86.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.